February 11, 2026 05:28 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Bangladesh poll manifestos mirror India’s welfare schemes as BNP, Jamaat bet big on women, freebies | Drama ends: Pakistan makes U-turn on India boycott, to play T20 World Cup clash as per schedule | ‘Won’t allow any impediment in SIR’: Supreme Court pulls up Mamata govt over delay in sharing officers’ details | India-US trade deal: ‘Negotiations always two-way’, says Amul MD amid farmers’ concerns | Khamenei breaks 37-year-old ritual for first time amid escalating Iran-US tensions | India must push for energy independence amid global uncertainty: Vedanta chairman Anil Agarwal | Kanpur horror: Lamborghini driven by businessman’s son rams vehicles, injures six | ‘Namaste Trump beat Howdy Modi’: Congress slams PM Over India-US trade deal | Historic India-US trade pact: Tariffs cut, $500B market opportunity unlocked! | Big call from RBI: Repo rate stays at 5.25%, neutral stance continues
Russia Sputnik V
Image Credit: Unsplash

Over 150 million Sputnik V doses distributed worldwide: Russia's Gamaleya Research

| @indiablooms | Sep 29, 2022, at 12:59 am

Moscow/IBNS: More than 150 million doses of the Sputnik V vaccine, developed by Russia’s Gamaleya Research Centre, have already been distributed around the world, including in the home country, the RGRC's Deputy Director Denis Logunov said on Wednesday.

"To date, based on a huge pool of data, more than 150 million doses of the Sputnik V vaccine have been produced and used in the world and in Russia.

"Huge safety and efficiency database has been accumulated," Logunov said at the international conference OpenBio-2022 in Russia’s science town of Koltsovo.

The accumulated data made it possible for Gamaleya Research Centre to expand the product line and develop Sputnik M, a vaccine for children aged 12-17, and produce a nasal version of the Sputnik V vaccine, which was registered on April 1, according to Logunov.

Clinical studies of the nasal vaccine showed a significant increase in antibody titer, the researcher said, adding that the Russian Health Ministry recommended two doses of the vaccine.

In addition, the research centre will soon begin clinical trials of a vaccine against the delta and omicron variants of COVID-19.

Meanwhile, the Ministry will allocate additional funding for a limited clinical trial for the development of a vaccine against the BA.5 coronavirus variant, Logunov noted.

At the same time, the effectiveness of the Sputnik V vaccine from getting infected by new strains of COVID-19 has decreased compared to the original strain, but the level of protection against lethality is still the same, he said.

Sputnik V, a combination vector vaccine for the prevention of COVID-19, was registered in Russia in August 2020.

Emergency mass distribution of the vaccine began in December 2020 in Russia and later in such countries as Argentina, Belarus, Hungary and Serbia.

As of January, the vaccine was authorized in more than 70 countries around the world.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.